Genvax Technologies

Ames, IA · Founded 2021 · Privately Held (backing)

Developer of animal vaccines designed to accelerate treatments for the animal health industry. Genvax Technologies is based in Ames, IA and was founded in 2021. Its last reported valuation was $25 million in Aug 2022. It has raised $8.4 million across 2 recorded rounds; the latest was a $3.4 million seed round in Jun 2024.

Last reported valuation
$25.0M
Oct 2026
Priced at
—
Total raised
$8.4M
Last round
Seed Round
Jun 2024
What is Genvax Technologies worth?
$25.0Mlast reported valuation · Oct 2026

Genvax Technologies's last reported valuation, Aug 2022. Nothing priced has surfaced since.

Free account
More of Genvax Technologies with a free account
  • ·The complete investor list: 11 names
  • ·Watch Genvax Technologies: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Genvax Technologies funding history

2 rounds
DateRoundRaisedPost-money
Jun 2024Seed Round$3.4M▮
Jun 2022Early Stage VC$6.4M▮
Unlock post-money valuations

Membership and data by Private Market View

Genvax Technologies valuation

Genvax Technologies's last reported valuation was $25 million in Aug 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Genvax Technologies raised?

Genvax Technologies has raised $8.4 million across 2 recorded rounds since 2022. The largest was a $6.4 million early-stage round in Jun 2022; the most recent was a $3.4 million seed round in Jun 2024.

Genvax Technologies has filed 2 Form Ds with the SEC since 2022, most recently in Jun 2024 ($3.4 million sold to 9 investors).

How Genvax Technologies's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Genvax Technologies, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →

Frequently asked about Genvax Technologies

What is Genvax Technologies worth?
Genvax Technologies is valued at $25.0M as of Oct 2026. Genvax Technologies's last reported valuation, Aug 2022. Nothing priced has surfaced since.
How much has Genvax Technologies raised?
Genvax Technologies has raised $8.4M in total funding across 2 recorded rounds.
When did Genvax Technologies last raise?
Genvax Technologies last raised in Jun 2024 (Seed Round), raising $3.4M.